Navigation Links
FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
Date:5/21/2009

ter degree in SAMSCA-treated patients compared to placebo-treated patients as early as 8 hours after the first dose, and the change was maintained for 30 days. The percentage of patients requiring fluid restriction (defined as less than 1L/day at any time during the treatment period) was also significantly less (p less than 0.0017) in the SAMSCA-treated group (30/215, 14 percent) as compared with the placebo-treated group (51/206, 25 percent).

In an open-label study (SALTWATER), 111 patients, 94 of whom were hyponatremic, who had previously been treated with either placebo or SAMSCA (and who had returned to standard of care for at least 7 days), were administered SAMSCA. Upon initiation of therapy, average serum sodium concentrations increased to approximately the same levels as observed for those patients previously treated with SAMSCA and were sustained for at least a year.

The safety of SAMSCA has been evaluated in more than 4,000 patients, approximately 650 of which had hyponatremia. Of these 650 patients, approximately 219 received SAMSCA for six months or more. In the two 30-day, double-blind, placebo-controlled trials, the most common adverse reactions (greater than or equal to 5 percent more frequently than in patients receiving placebo) observed in patients receiving SAMSCA (n equals 223, placebo n equals 220) were thirst (16 percent vs. 5 percent in placebo patients), dry mouth (13 percent vs. 4 percent), asthenia (9 percent vs. 4 percent), constipation (7 percent vs. 2 percent), pollakiuria or polyuria (11 percent vs. 3 percent), and hyperglycemia (6 percent vs. 1 percent). In these studies, 10 percent of SAMSCA patients discontinued therapy due to adverse reactions compared to 12 percent of placebo-treated patients.

About Hyponatremia

Hyponatremia, a common electrolyte disorder in hospitals, occurs in as many as 6 million people in the United States or 15-20 percent of hospitalized p
'/>"/>

SOURCE Otsuka Pharmaceutical Co., Ltd.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Georgia (PRWEB) May 22, 2013 ... finalists for its Better Play & Recreation Contest, ... hundreds of thousands of youth, people with disabilities, ... need of rescue. The general public is encouraged ... to help their favorite non-profit organization win the ...
(Date:5/22/2013)... 2013 BroadConnect Telecom, the leading ... security solutions in North America announced plans to ... newest BroadConnect hosted security solutions. Available on premise, ... BroadConnect’s new Security as a Service (SaaS) enables ... connection of their choice, while optimizing internal network ...
(Date:5/22/2013)... May 22, 2013 Patients with type ... therapy have better glycemic control as measured by significantly ... their condition with insulin injections, according to new findings ... (NHWS), conducted by Kantar Health . The research ... ISPOR (International Society for Pharmacoeconomics and Outcomes Research) in ...
(Date:5/22/2013)... May 22, 2013 The Report ... Resins, Melamine Formaldehyde, Melamine Urea Formaldehyde), Applications (Particle ... Global Trends and Forecasts to 2018" defines and ... of the global volume and revenue. , ... the Global Amino Resins Market with analysis of ...
(Date:5/21/2013)... May 21, 2013 Heritage Woods of ... BMA affordable assisted living community, is hosting a Quality Home ... at 2 p.m. on Tuesday, May 28. , The community, ... serves older adults of all incomes, including those on Medicaid, ... Arthritis program is open to the public. There is ...
Breaking Medicine News(10 mins):Health News:Public Voting Opens for Finalists in Synthetic Turf International’s Better Play & Recreation Contest 2Health News:BroadConnect Telecom to Launch Enterprise-Grade Hosted Security Solutions Engineered to Meet the Demands of Real World Business 2Health News:Insulin Pump Therapy Provides Better Glycemic Control Among Type 1 Diabetics, According to Kantar Health Research 2Health News:Insulin Pump Therapy Provides Better Glycemic Control Among Type 1 Diabetics, According to Kantar Health Research 3Health News:Asia-Pacific Leads in Consumption of Urea Formaldehyde Resins Followed by Europe and North America - New Report by MarketsandMarkets 2Health News:Asia-Pacific Leads in Consumption of Urea Formaldehyde Resins Followed by Europe and North America - New Report by MarketsandMarkets 3Health News:Heritage Woods of Dwight Affordable Assisted Living to Host Informational Program on the Do's and Don'ts of Arthritis 2
... guidelines for school sports, survey shows , WEDNESDAY, June ... on concussions in school sports, the majority are unaware ... most report widespread pressure to return young athletes to ... came from the C.S. Mott Children,s Hospital National Poll ...
... ... senior living communities. A senior care blog and Q&A area also offer helpful advice ... ... 2010 -- AssistedLivingFacilities.org is a new website that has launched to help senior citizens ...
... Dr. DeSilva hosts ... , ... 2010-- Want a chance to ask the health experts? Swanson Health Talk Radio, hosted by ... and authors questions covering the topics of vitamins and supplements, homeopathic medicine, exercise and fitness, ...
... ... and fitness fun for the whole family. Free to download with $.99 in-app purchase to ... streetball players and ball handlers. , ... Los Angeles, CA (PRWEB) June 16, 2010 -- Luis Da Silva Jr. aka TRIKZ ...
... ... above its laser lipolysis competitors by empowering its patients with education about liposuction and body ... ... standard of Soluna MD is its commitment to patient education. The Soluna MD staff, led ...
... ... aiding in the creation of healthy serotonin levels , ... Springville, UT (PRWEB) June 16, 2010 -- Nutrifect introduces Serofil, a ... restful sleep ; reduces cravings for junk food; and assists with healthy fat loss ...
Cached Medicine News:Health News:Parents Ill-Informed About Kids' Concussion Risks 2Health News:Seniors Have a New Resource to Research Assisted Living Housing Options 2Health News:Seniors Have a New Resource to Research Assisted Living Housing Options 3Health News:Dr. DeSilva Hosts Swanson Health Talk Radio on HealthRadio.net 2Health News:Dr. DeSilva Hosts Swanson Health Talk Radio on HealthRadio.net 3Health News:Trikz Streetball Basketball iTunes App Promotion: Only $.99 to Unlock All Content for the iPhone, iPod Touch, and iPad 2Health News:Trikz Streetball Basketball iTunes App Promotion: Only $.99 to Unlock All Content for the iPhone, iPod Touch, and iPad 3Health News:Miami's Soluna MD Educates Patients, Gains International Reputation for Excellence in Laser Lipo plus Ultrasound Technique, SmartLipo™ Ultra 2Health News:Miami's Soluna MD Educates Patients, Gains International Reputation for Excellence in Laser Lipo plus Ultrasound Technique, SmartLipo™ Ultra 3Health News:Healthy Serotonin Levels Shown to Positively Affect many Important Functions of the Mind and Body. 2
(Date:5/22/2013)... VANCOUVER, British Columbia , May 22, 2013  OncoGenex ... the development of novel therapeutics to target mechanisms of treatment ... investigational compounds, custirsen and OGX-427, will be presented as "Trials ... of the American Society of Clinical Oncology (ASCO) in ... 4. Despite the availability of drugs that ...
(Date:5/21/2013)... 2013  NxStage Medical, Inc. (Nasdaq: NXTM ... announced that it has entered into new agreements covering ... to DaVita, the kidney care division of DaVita Healthcare Partners ... For the use of products for home hemodialysis ... has executed a second amended and restated National Service ...
(Date:5/21/2013)... Calif. , May 21, 2013   Regulus ... company leading the discovery and development of innovative medicines ... Menzel , Ph.D., Chief Operating Officer and Executive ... the Deutsche Bank 38th Annual Healthcare Conference on Wednesday, ... is being held at the Westin Boston Waterfront Hotel. ...
Breaking Medicine Technology:OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 2OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 3OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 4OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 5NxStage Announces New Agreements with DaVita 2Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference 2
... Inc. (NASDAQ: DCTH ) announced today that ... to the Company,s request made in September for a ... date in mid-January 2012.  Delcath plans to submit the ... treatment of patients with metastatic melanoma in the liver ...
... Mass., Oct. 26, 2011 Idenix Pharmaceuticals, Inc. (NASDAQ: ... financial results for the third quarter of 2011 on Wednesday, ... Idenix management will host a conference call at 4:30 p.m. ... financial results for the third quarter of 2011 and provide ...
Cached Medicine Technology:FDA Schedules Delcath Pre-New Drug Application Meeting Date 2FDA Schedules Delcath Pre-New Drug Application Meeting Date 3Idenix to Host Conference Call Discussing Third Quarter and Nine Month 2011 Financial Results and Announces Presentations at the American Association for the Study of Liver Diseases Meeting (AASLD) 2
The Storz Protege is an anterior segment unit only....
The Storz Premiere comes as anterior, posterior and anterior/posterior combo. The combo provides the following modes irrigation, irrigation/aspiration, vitrectomy, and illumination....
Compact ultrasonic phacoemulsification system....
... Precisionist workstation is a unique combination ... allowing infinite flexibility for modular hardware ... the demands of changing cataract surgical ... concept in ophthalmic surgical platforms providing ...
Medicine Products: